Shilpa Medicare Limited has submitted to the Exchange, Outcome of Board meeting held today, i.e., on 22 May 2026
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board of Directors approved Shilpa Medicare's FY2025-26 audited financial results showing strong growth. Standalone revenue grew to Rs 59,703 lakhs with net profit of Rs 13,297 lakhs (EPS Rs 6.80), while consolidated revenue reached Rs 153,887 lakhs with net profit of Rs 24,333 lakhs. The Board recommended a final dividend of Rs 0.60 per equity share (60%) for FY2025-26, subject to shareholder approval. Additionally, the company's wholly-owned subsidiaries will invest Rs 4.44 crore for a 28% equity stake in Neo Green Power Project Private Limited for captive renewable energy consumption. The Board also approved shifting the registered office from Karnataka to Maharashtra. Auditors gave unmodified opinions on both standalone and consolidated financials.
Strong financial performance with near-doubling of standalone EPS and positive consolidated growth should support the stock. Dividend payout demonstrates confidence in cash flows. The office relocation and green energy investment indicate strategic expansion plans that could attract long-term investors.